In schizophrenia, psychomotor retardation is associated with executive and memory impairments, negative and psychotic symptoms, neurotoxic immune products and lower natural IgM to malondialdehyde

References

• Amara A, Constans J, Chaugier C, Sebban A, Dubourg L, Peuchant E, Pellegrin JL, Leng B, Conri C, Geffard M. 1995. Autoantibodies to malondialdehyde-modified epitope in connective tissue diseases and vasculitides. Clin Exp Immunol. 101(2):233–238.
   PubMed Web of Science ®Google Scholar
• Anderson G, Maes M. 2013. Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment, and neuroprogression. Prog Neuropsychopharmacol Biol Psychiatry. 42:5–19.
   PubMed Web of Science ®Google Scholar
• Andreasen NC. 1989. The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry. 7:49–58.
   Google Scholar
• Barbas H. 2009. Prefrontal Cortex: Structure and Anatomy. In: Squire LR, editor. Encyclopedia of Neuroscience. Elsevier, Academic Press; p. 909–918.
   Google Scholar
• Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, et al. 2002. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 159(6):1018–1028.
   PubMed Web of Science ®Google Scholar
• Boullerne A, Petry KG, Geffard M. 1996. Circulating antibodies directed against conjugated fatty acids in sera of patients with multiple sclerosis. J Neuroimmunol. 65(1):75–81.
   PubMed Web of Science ®Google Scholar
• Boullerne AI, Petry KG, Meynard M, Geffard M. 1995. Indirect evidence for nitricoxide involvement in multiple sclerosis by characterization of circulating antibodies directed against conjugated S-nitrosocysteine. J Neuroimmunol. 60(1-2):117–124.
   PubMed Web of Science ®Google Scholar
• Boullerne AI, Rodrı́guez JJ, Touil T, Brochet B, Schmidt S, Abrous ND, Le Moal M, Pua JR, Jensen MA, Mayo W, et al. 2002. Anti-S-nitrosocysteine antibodies are a predictive marker for demyelination in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. J Neurosci. 22(1):123–132.
   PubMed Web of Science ®Google Scholar
• Braw Y, Bloch Y, Mendelovich S, Ratzoni G, Gal G, Harari H, Tripto A, Levkovitz Y. 2007. Cognition in young schizophrenia outpatients: comparison of first-episode with multi-episode patients. Schizophr Bull. 34(3):544–554.
   PubMed Web of Science ®Google Scholar
• Brébion G, Amador X, Smith M, Malaspina D, Sharif Z, Gorman JM. 2000. Depression, psychomotor retardation, negative symptoms, and memory in schizophrenia. Neuropsychiatry Neuropsychol Behav Neurol. 13(3):177–183.
   PubMedGoogle Scholar
• CANTAB. 2018. The most validated cognitive research software. http://www.cambridgecognition.com/cantab/. October 1, 2018.
   Google Scholar
• Carnahan H, Aguilar O, Malla A, Norman R. 1997. An investigation into movement planning and execution deficits in individuals with schizophrenia. Schizophr Res. 23(3):213–221.
   PubMed Web of Science ®Google Scholar
• CERAD. 1986. CERAD – An Overview: The Consortium to Establish a Registry for Alzheimer’s Disease; http://cerad.mc.duke.edu/.
   Google Scholar
• Corti EJ, Johnson AR, Riddle H, Gasson N, Kane R, Loftus AM. 2017. The relationship between executive function and fine motor control in young and older adults. Hum Mov Sci. 51:41–50.
   PubMed Web of Science ®Google Scholar
• Daverat P, Geffard M, Orgogozo JM. 1989. Identification and characterization of anti-conjugated azelaic acid antibodies in multiple sclerosis. J Neuroimmunol. 22(2):129–134.
   PubMed Web of Science ®Google Scholar
• Davis J, Eyre H, Jacka FN, Dodd S, Dean O, McEwen S, Debnath M, McGrath J, Maes M, Amminger P, et al. 2016. A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis. Neurosci Biobehav Rev. 65:185–194.
   PubMed Web of Science ®Google Scholar
• Davis J, Moylan S, Harvey BH, Maes M, Berk M. 2014. Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries. Aust N Z J Psychiatry. 48(6):512–529.
   PubMed Web of Science ®Google Scholar
• Duleu S, Mangas A, Sevin F, Veyret B, Bessede A, Geffard M. 2010. Circulating Antibodies to IDO/THO Pathway Metabolites in Alzheimer's Disease. Int J Alzheimers Dis. 15;2010. pii: :501541.
   Google Scholar
• Dzhupanov G, Haralanov S, Terziivanova P, Haralanova E. 2017. Objectively measurable equilibriometric locomotor ataxia in schizophrenia. Eur Psychiatry. 41(Supplement April 2017):S810.
   Web of Science ®Google Scholar
• Faiderbe S, Chagnaud JL, Geffard M. 1992. Anti-phosphoinositide auto-antibodies in sera of cancer patients: isotypic and immunochemical characterization. Cancer Lett. 66(1):35–41.
   PubMed Web of Science ®Google Scholar
• Frith CD. 1995. The cognitive neuropsychology of schizophrenia. Lawrence Erlbaum. p. 53. ISBN 978-0-86377-334-1.
   Google Scholar
• Fuller R, Jahanshahi M. 1999. Concurrent performance of motor tasks and processing capacity in patients with schizophrenia. J Neurol Neurosurg Psychiatry. 66(5):668–671.
   PubMed Web of Science ®Google Scholar
• Fuster JM. 2009. Prefrontal Cortex. In: Squire LR, editor. Encyclopedia of Neuroscience. Elsevier, Academic Press; p. 905–908.
   Google Scholar
• Geffard M, Bodet D, Dabadie MP, Arnould L. 2003. Identification of antibodies in sera of breast cancer patients. Immuno-Analyse & Biologie Special. 18:248–253.
   Google Scholar
• Goldsmith DR, Haroon E, Woolwine BJ, Jung MY, Wommack EC, Harvey PD, Treadway MT, Felger JC, Miller AH. 2016. Inflammatory markers are associated with decreased psychomotor speed in patients with major depressive disorder. Brain Behav Immun. 56:281–288.
   PubMed Web of Science ®Google Scholar
• Grootens KP, Vermeeren L, Verkes RJ, Buitelaar JK, Sabbe BG, van Veelen N, Kahn RS, Hulstijn W. 2009. Psychomotor planning is deficient in recent-onset schizophrenia. Schizophr Res. 107(2-3):294–302.
   PubMed Web of Science ®Google Scholar
• Hamdioui S, Lotfi S. 2016. Psychomotor Disorders in Schizophrenia: A Systematic Review. Middle-East J Sci Res. 24 (4):1078–1085.
   Google Scholar
• Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry. 23(1):56–62.
   PubMed Web of Science ®Google Scholar
• Haralanov S, Claussen CF, Haralanova E, Shkodrova D. 2002. Computerized ultrasonographic craniocorpography and abnormal psychomotor activity in psychiatric patients. Int Tinnitus J. 8(2):72–76.
   PubMedGoogle Scholar
• Haralanov S, Haralanova E, Milushev E, Shkodrova D, Claussen CF. 2018. Objective and quantitative equilibriometric evaluation of individual locomotor behaviour in schizophrenia: Translational and clinical implications. J Eval Clin Pract. 24(4):815–825.
   PubMed Web of Science ®Google Scholar
• Henkel V, Mergl R, Schäfer M, Rujescu D, Möller HJ, Hegerl U. 2004. Kinematical analysis of motor function in schizophrenic patients: a possibility to separate negative symptoms from extrapyramidal dysfunction induced by neuroleptics? Pharmacopsychiatry. 37(3):110–118.
   PubMed Web of Science ®Google Scholar
• Heuninchx S, Wenderoth N, Swinnen SP. 2008. Systems neuroplasticity in the brain: Recruiting additional neural resources for successful motor performance in elderly persons. J Neurosci. 28 (1):91–99.
   PubMed Web of Science ®Google Scholar
• Hobart MP, Goldberg R, Bartko JJ, Gold JM. 1999. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia, II: convergent/discriminant validity and diagnostic group comparisons. Am J Psychiatry. 156(12):1951–1957.
   PubMed Web of Science ®Google Scholar
• Holthausen EA, Wiersma D, Knegtering RH, Van den Bosch RJ. 1999. Psychopathology and cognition in schizophrenia spectrum disorders: the role of depressive symptoms. Schizophr Res. 39(1):65–71.
   PubMed Web of Science ®Google Scholar
• Jogems-Kosterman BJ, Zitman FG, Van Hoof JJ, Hulstijn W. 2001. Psychomotor slowing and planning deficits in schizophrenia. Schizophr Res. 48(2-3):317–333.
   PubMed Web of Science ®Google Scholar
• Kanchanatawan B, Hemrungrojn S, Thika S, Sirivichayakul S, Ruxrungtham K, Carvalho AF, Geffard M, Anderson G, Maes M. 2018a. Changes in tryptophan catabolite (TRYCAT) pathway patterning are associated with mild impairments in declarative memory in schizophrenia and deficits in semantic and episodic memory coupled with increased false-memory creation in deficit schizophrenia. Mol Neurobiol. 55(6):5184–5201.
   PubMed Web of Science ®Google Scholar
• Kanchanatawan B, Sriswasdi S, Thika S, Sirivichayakul S, Carvalho AF, Geffard M, Kubera M, Maes M. 2018b. Deficit schizophrenia is a discrete diagnostic category defined by neuro-immune and neurocognitive features: results of supervised machine learning. Metab Brain Dis. 33(4):1053–1067.
   PubMed Web of Science ®Google Scholar
• Kanchanatawan B, Sriswasdi S, Thika S, Stoyanov D, Sirivichayakul S, Carvalho AF, Geffard M, Maes M. 2018c. Towards a new classification of stable phase schizophrenia into major and simple neuro-cognitive psychosis: Results of unsupervised machine learning analysis. J Eval Clin Pract. 24(4):879–891.
   PubMed Web of Science ®Google Scholar
• Kanchanatawan B, Thika S, Sirivichayakul S, Carvalho AF, Geffard M, Maes M. 2018d. In schizophrenia, depression, anxiety, and physiosomatic symptoms are strongly related to psychotic Symptoms and Excitation, impairments in episodic memory, and increased production of neurotoxic tryptophan catabolites: a multivariate and machine learning study. Neurotox Res. 33(3):641–655.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 13(2):261–276.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B, Buchanan R W, McKenny P D, Alphs L D, Carpenter W T. Jr. 1989. The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 30(2):119–123.
   PubMed Web of Science ®Google Scholar
• Kittirathanapaiboon P, Khamwongpin M. 2005. The validity of the Mini International Neuropsychiatric Interview (M.I.N.I.) Thai Version. J Mental Health Thailand. 13(3):125–135.
   Google Scholar
• Kontaxaki MI, Kattoulas E, Smyrnis N, Stefanis NC. 2014. Cognitive impairments and psychopathological parameters in patients of the schizophrenic spectrum. Psychiatriki. 25(1):27–38.
   PubMedGoogle Scholar
• Leisman G, Moustafa AA, Shafir T. 2016. Thinking, walking, talking: integratory motor and cognitive brain function. Front Public Health. 25(4):94.
   Google Scholar
• Liu T, Slotnick SD, Serences JT, Yantis S. 2003. Cortical mechanisms of feature-based attentional control. Cereb Cortex. 13(12):1334–1343.
   PubMed Web of Science ®Google Scholar
• Maes M, Bosmans E, Kenis G, De Jong R, Smith RS, Meltzer HY. 1997a. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res. 26(2–3):221–225.
   PubMed Web of Science ®Google Scholar
• Maes M, Bosmans E, Ranjan R, Vandoolaeghe E, Meltzer HY, De Ley M, Berghmans R, Stans G, Desnyder R. 1996. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr Res. 21(1):39–50.
   PubMed Web of Science ®Google Scholar
• Maes M, Carvalho AF. 2018. The Compensatory Immune-Regulatory Reflex System (CIRS) in depression and bipolar disorder. Mol Neurobiol. 55(12):8885–8903.
   PubMed Web of Science ®Google Scholar
• Maes M, Delange J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W, Scharpé S. 1997b. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res. 66(1):1–11.
   PubMed Web of Science ®Google Scholar
• Maes M, Kanchanatawan B, Sirivichayakul S, Carvalho AF. 2019. In schizophrenia, deficits in natural igm isotype antibodies including those directed to malondialdehyde and azelaic acid strongly predict negative symptoms, neurocognitive impairments, and the deficit syndrome. Mol Neurobiol. 56(7):5122–5135.
   PubMed Web of Science ®Google Scholar
• Maes M, Meltzer HY, Bosmans E. 1994. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand. 89(5):346–351.
   PubMed Web of Science ®Google Scholar
• Maes M, Meltzer HY, Scharpé S, Cooreman W, Uyttenbroeck W, Suy E, Vandervorst C, Calabrese J, Raus J, Cosyns P. 1993. Psychomotor retardation, anorexia, weight loss, sleep disturbances, and loss of energy: psychopathological correlates of hyperhaptoglobinemia during major depression. Psychiatry Res. 47(3):229–241.
   PubMed Web of Science ®Google Scholar
• Mahurin RK, Velligan DI, Hazleton B, Mark Davis J, Eckert S, Miller AL. 2006. Trail making test errors and executive function in schizophrenia and depression. Clin Neuropsychol. 20(2):271–288.
   PubMed Web of Science ®Google Scholar
• Mahurin RK, Velligan DI, Miller AL. 1998. Executive-frontal lobe cognitive dysfunction in schizophrenia: a symptom subtype analysis. Psychiatry Res. 79(2):139–149.
   PubMed Web of Science ®Google Scholar
• Malla AK, Norman RM, Aguilar O, Carnahan H, Cortese L. 1995. Relationship between movement planning and psychopathology profiles in schizophrenia. Br J Psychiatry. 167(2):211–215.
   PubMedGoogle Scholar
• Morrens M, Hulstijn W, Sabbe B. 2007. Psychomotor slowing in schizophrenia. Schizophr Bull. 33(4):1038–1053.
   PubMed Web of Science ®Google Scholar
• Noto MN, Maes M, Nunes SO, Ota VK, Rossaneisf AC, Verri WA, Jr Cordeiro Q, Belangero SI, Gadelha A, Bressan RA, et al. 2018. Activation of the immune-inflammatory response system and the compensatory immune-regulatory reflex system in antipsychotic naive first episode psychosis. Preprints Preprints201809. 0314:v2.
   Google Scholar
• Overall JE, Gorham DR. 1962. The brief psychiatric rating scale. PR. 10(3):799–812.
   Google Scholar
• Putzhammer A, Heindl B, Broll K, Pfeiff L, Perfahl M, Hajak G. 2004. Spatial and temporal parameters of gait disturbances in schizophrenic patients. Schizophr Res. 69(2–3):159–166.
   PubMed Web of Science ®Google Scholar
• Rabbitt P, Lowe C. 2000. Patterns of cognitive ageing. Psychol Res. 63(3-4):308–316.
   PubMed Web of Science ®Google Scholar
• Riddle H. 2013. The contribution of executive functioning to fine motor control in healthy ageing. Dissertation submitted by Hayley Riddle, 8th November, 2013, Curtin University, Western Australia.
   Google Scholar
• Ringle CM, da Silva D, Bido D. 2014. Structural equation modeling with the SmartPLS. REMark. 13(2):56–73.
   Google Scholar
• Roomruangwong C, Kanchanatawan B, Carvalho AF, Sirivichayakul S, Duleu S, Geffard M, Maes M. 2018. Body image dissatisfaction in pregnant and non-pregnant females is strongly predicted by immune activation and mucosa-derived activation of the tryptophan catabolite (TRYCAT) pathway. World J Biol Psychiatry. 19(3):200–209.
   PubMed Web of Science ®Google Scholar
• Roomruangwong C, Kanchanatawan B, Sirivichayakul S, Anderson G, Carvalho AF, Duleu S, Geffard M, Maes M. 2017. IgA/IgM responses to tryptophan and tryptophan catabolites (TRYCATs) are differently associated with prenatal depression, physio-somatic symptoms at the end of term and premenstrual syndrome. Mol Neurobiol. 54(4):3038–3049.
   PubMed Web of Science ®Google Scholar
• Roomruangwong C, Noto C, Kanchanatawan B, Anderson G, Kubera M, Carvalho AF, Maes M. 2019. The role of aberrations in the immune-inflammatory response system (IRS) and the compensatory immune-regulatory reflex system (CIRS) in different phenotypes of schizophrenia: the IRS-CIRS theory of schizophrenia. Mol Neurobiol. DOI:10.1007/s12035-019-01737-z
   PubMed Web of Science ®Google Scholar
• Schröder J, Essig M, Baudendistel K, Jahn T, Gerdsen I, Stockert A, Schad LR, Knopp MV. 1999. Motor dysfunction and sensorimotor cortex activation changes in schizophrenia: A study with functional magnetic resonance imaging. Neuroimage. 9(1):81–87.
   PubMed Web of Science ®Google Scholar
• Seidler R D, Bernard J A, Burutolu T B, Fling B W, Gordon M T, Gwin J T, Kwak Y, Lipps D B. 2010. Motor control and aging: Links to age-related brain structural, functional and biochemical effects. Neurosci Biobehav Rev. 34(5):721–733.
   PubMed Web of Science ®Google Scholar
• Sirivichayakul S, Kanchanatawan B, Thika S, Carvalho AF, Maes M. 2019a. A new schizophrenia model: immune activation is associated with induction of different neurotoxic products which together determine memory impairments and schizophrenia symptom dimensions. CNS Neurol Disord Drug Targets. 18(2):124–140.
   PubMed Web of Science ®Google Scholar
• Sirivichayakul S, Kanchanatawan B, Thika S, Carvalho AF, Maes M. 2019b. Eotaxin, an endogenous Cognitive Deteriorating Chemokine (ECDC), is a major contributor to cognitive decline in normal people and to executive, memory, and sustained attention deficits, formal thought disorders, and psychopathology in schizophrenia patients. Neurotox Res. 35(1):122–138.
   PubMed Web of Science ®Google Scholar
• Smith RS, Maes M. 1995. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med Hypotheses. 45(2):135–141.
   PubMed Web of Science ®Google Scholar
• Walther S, Strik W. 2012. Motor symptoms and schizophrenia. Neuropsychobiology. 66(2):77–92.
   PubMed Web of Science ®Google Scholar
• Woodward ND, Purdon SE, Meltzer HY, Zald DH. 2005. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharm. 8(3):457–472.
   PubMed Web of Science ®Google Scholar